112 related articles for article (PubMed ID: 29336525)
21. Evaluation of continence following 532 nm laser prostatectomy for patients previously treated with radiation therapy or brachytherapy.
No D; Osterberg EC; Otto B; Naftali I; Choi B
Lasers Surg Med; 2013 Aug; 45(6):358-61. PubMed ID: 23813669
[TBL] [Abstract][Full Text] [Related]
22. New Rates of Interventions to Manage Complications of Modern Prostate Cancer Treatment in Older Men.
Wallis CJ; Mahar A; Cheung P; Herschorn S; Klotz LH; Al-Matar A; Kulkarni GS; Lee Y; Kodama RT; Narod SA; Nam RK
Eur Urol; 2016 May; 69(5):933-41. PubMed ID: 26572707
[TBL] [Abstract][Full Text] [Related]
23. Commentary on "secondary cancers after intensity-modulated radiotherapy, brachytherapy, and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention." Zelefsky MJ, Pei X, Teslova T, Kuk D, Magsanoc JM, Kollmeier M, Cox B, Zhang Z. Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY.: BJU Int 2012;110:1696-701. doi: 10.1111/j.1464-410X.2012.11385.x. [Epub 2012 Aug 13].
Gottschalk A
Urol Oncol; 2014 Feb; 32(2):209. PubMed ID: 24445290
[TBL] [Abstract][Full Text] [Related]
24. Does Seed Migration Increase the Risk of Second Malignancies in Prostate Cancer Patients Treated With Iodine-125 Loose Seeds Brachytherapy?
Vigneault E; Martell K; Taussky D; Husain S; Delouya G; Mbodji K; Piotte J; Magnan S; Després P; Lavallée MC; Aubin S; Beaulieu L; Foster W; Martin AG
Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1190-1194. PubMed ID: 29428250
[TBL] [Abstract][Full Text] [Related]
25. Toxicity after external beam radiotherapy for prostate cancer: an analysis of late morbidity in men with diabetes mellitus.
Kalakota K; Liauw SL
Urology; 2013 Jun; 81(6):1196-201. PubMed ID: 23540863
[TBL] [Abstract][Full Text] [Related]
26. Postoperative Radiation Therapy for Prostate Cancer: Comparison of Conventional Versus Hypofractionated Radiation Regimens.
Tandberg DJ; Oyekunle T; Lee WR; Wu Y; Salama JK; Koontz BF
Int J Radiat Oncol Biol Phys; 2018 Jun; 101(2):396-405. PubMed ID: 29559284
[TBL] [Abstract][Full Text] [Related]
27. Association of colorectal cancer and prostate cancer and impact of radiation therapy.
Huo D; Hetzel JT; Roy H; Rubin DT
Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):1979-85. PubMed ID: 19531678
[TBL] [Abstract][Full Text] [Related]
28. Radiation therapy for prostate cancer increases the risk of subsequent rectal cancer.
Margel D; Baniel J; Wasserberg N; Bar-Chana M; Yossepowitch O
Ann Surg; 2011 Dec; 254(6):947-50. PubMed ID: 22107741
[TBL] [Abstract][Full Text] [Related]
29. Multiple primary malignancies in patients with prostate cancer: increased risk of secondary malignancies after radiotherapy.
Okajima K; Ishikawa K; Matsuura T; Tatebe H; Fujiwara K; Hiroi K; Hasegawa H; Nishimura Y
Int J Clin Oncol; 2013 Dec; 18(6):1078-84. PubMed ID: 23179638
[TBL] [Abstract][Full Text] [Related]
30. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L
Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359
[TBL] [Abstract][Full Text] [Related]
31. Cumulative Incidence and Clinical Risk Factors of Radiation Cystitis after Radiotherapy for Prostate Cancer.
Makino K; Sato Y; Takenaka R; Yamashita H; Akiyama Y; Yamada Y; Nakamura M; Kawai T; Yamada D; Suzuki M; Kume H
Urol Int; 2023; 107(5):440-446. PubMed ID: 35290980
[TBL] [Abstract][Full Text] [Related]
32. Rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer (Int J Radiat Oncol Biol Phys 2010;76:342-348).
Hyde C
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1607; author reply 1607. PubMed ID: 20637987
[No Abstract] [Full Text] [Related]
33. [Functional and oncological outcome of salvage prostatectomy of locally recurrent prostate cancer following radiation therapy].
Heidenreich A; Ohlmann C; Ozgür E; Engelmann U
Urologe A; 2006 Apr; 45(4):474-81. PubMed ID: 16465521
[TBL] [Abstract][Full Text] [Related]
34. Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment.
Loeb S; Folkvaljon Y; Robinson D; Schlomm T; Garmo H; Stattin P
Eur Urol; 2016 Nov; 70(5):824-828. PubMed ID: 26743040
[TBL] [Abstract][Full Text] [Related]
35. Long-term adverse effects after curative radiotherapy and radical prostatectomy: population-based nationwide register study.
Fridriksson JÖ; Folkvaljon Y; Nilsson P; Robinson D; Franck-Lissbrant I; Ehdaie B; Eastham JA; Widmark A; Karlsson CT; Stattin P
Scand J Urol; 2016 Oct; 50(5):338-45. PubMed ID: 27333148
[TBL] [Abstract][Full Text] [Related]
36. Commentary on "Toxicity after external beam radiotherapy for prostate cancer: an analysis of late morbidity in men with diabetes mellitus." Kalakota K, Liauw SL, Department of Radiation Oncology, Northwestern Memorial Hospital, Chicago, IL.: Urology 2013;81(6):1196-201. doi: 10.1016/j.urology.2013.01.047. [Epub 2013 Mar 26].
Gottschalk A
Urol Oncol; 2014 Apr; 32(3):374. PubMed ID: 24679464
[TBL] [Abstract][Full Text] [Related]
37. Cancer incidence after localized therapy for prostate cancer.
Moon K; Stukenborg GJ; Keim J; Theodorescu D
Cancer; 2006 Sep; 107(5):991-8. PubMed ID: 16878323
[TBL] [Abstract][Full Text] [Related]
38. Phase 2 trial of guideline-based postoperative image guided intensity modulated radiation therapy for prostate cancer: Toxicity, biochemical, and patient-reported health-related quality-of-life outcomes.
Berlin A; Cho E; Kong V; Howell KJ; Lao B; Craig T; Bayley A; Chung P; Gospodarowicz M; Warde P; Catton C; Bristow RG; Ménard C
Pract Radiat Oncol; 2015; 5(5):e473-e482. PubMed ID: 25899220
[TBL] [Abstract][Full Text] [Related]
39. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
40. Time Course and Accumulated Risk of Severe Urinary Adverse Events After High- Versus Low-Dose-Rate Prostate Brachytherapy With or Without External Beam Radiation Therapy.
Tward JD; Jarosek S; Chu H; Thorpe C; Shrieve DC; Elliott S
Int J Radiat Oncol Biol Phys; 2016 Aug; 95(5):1443-1453. PubMed ID: 27325475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
